These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18434649)

  • 21. Shattuck lecture. Innovation, regulation, and the FDA.
    Hamburg MA
    N Engl J Med; 2010 Dec; 363(23):2228-32. PubMed ID: 21121835
    [No Abstract]   [Full Text] [Related]  

  • 22. Sales of contaminated animal drugs halted.
    Henkel J
    FDA Consum; 1999; 33(5):34. PubMed ID: 10522171
    [No Abstract]   [Full Text] [Related]  

  • 23. Tobacco, public health, and the FDA.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2009 Jul; 361(4):402-3. PubMed ID: 19546344
    [No Abstract]   [Full Text] [Related]  

  • 24. Regulatory science and the role of the regulator in biomedical innovation.
    Honig PK; Huang SM
    Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages.
    Hunnisett-Dritz D
    Am J Health Syst Pharm; 2012 Oct; 69(19):1626, 1628. PubMed ID: 22997113
    [No Abstract]   [Full Text] [Related]  

  • 26. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 27. A sick agency in need of a cure? Recall of a popular pain drug has focused attention on government drug regulation.
    Spake A
    US News World Rep; 2004 Dec; 137(21):32-3, 36. PubMed ID: 15636503
    [No Abstract]   [Full Text] [Related]  

  • 28. Forbidden and Permitted Statements about Medications--Loosening the Rules.
    Avorn J; Sarpatwari A; Kesselheim AS
    N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
    [No Abstract]   [Full Text] [Related]  

  • 29. Schering-Plough agrees to pay FDA $500 million and bring factories into compliance.
    Kuehn BM
    J Am Vet Med Assoc; 2002 Jul; 221(2):174, 180. PubMed ID: 12118571
    [No Abstract]   [Full Text] [Related]  

  • 30. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 31. A lost opportunity for public health--the FDA advisory committee report on menthol.
    Siegel M
    N Engl J Med; 2011 Jun; 364(23):2177-9. PubMed ID: 21542736
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 33. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 34. What ails the FDA?
    Marcus DM
    N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962405
    [No Abstract]   [Full Text] [Related]  

  • 35. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 36. Regulation of compounding by the food and drug administration: a tale of 2 circuits.
    Williams KG
    J Pharm Pract; 2010 Oct; 23(5):502-6. PubMed ID: 21507854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. User fees to hasten FDA review.
    Gershon D
    Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
    [No Abstract]   [Full Text] [Related]  

  • 38. The FDA as a public health agency.
    Hamburg MA; Sharfstein JM
    N Engl J Med; 2009 Jun; 360(24):2493-5. PubMed ID: 19470577
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.